Ophthalmic Drugs Market 2028 By Disease, Drug Class, Product Type | The Insight Partners

Ophthalmic Drugs Market Forecast to 2028 - Covid-19 Impact and Global Analysis - By Disease (Dry Eye, Allergies, Glaucoma, Retinal Disorders, Others); Drug Class (Anti-Glaucoma Drug, Dry Eye Drug, Ophthalmic Anti-Allergy/Inflammatory, Retinal drug, Others); Product Type (OTC Drug, Prescription Drug)

Report Code: TIPRE00008651 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Ophthalmic Drugs - By Disease
1.3.2 Ophthalmic Drugs - By Drug Class
1.3.3 Ophthalmic Drugs - By Product Type
1.3.4 Ophthalmic Drugs - By Region
1.3.4.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. OPHTHALMIC DRUGS LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. OPHTHALMIC DRUGS - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. OPHTHALMIC DRUGS - GLOBAL MARKET ANALYSIS
6.1. OPHTHALMIC DRUGS - GLOBAL MARKET OVERVIEW
6.2. OPHTHALMIC DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE

7. OPHTHALMIC DRUGS - REVENUE AND FORECASTS TO 2028 - DISEASE
7.1. OVERVIEW
7.2. DISEASE MARKET FORECASTS AND ANALYSIS
7.3. DRY EYE
7.3.1. Overview
7.3.2. Dry Eye Market Forecast and Analysis
7.4. ALLERGIES
7.4.1. Overview
7.4.2. Allergies Market Forecast and Analysis
7.5. GLAUCOMA
7.5.1. Overview
7.5.2. Glaucoma Market Forecast and Analysis
7.6. RETINAL DISORDERS
7.6.1. Overview
7.6.2. Retinal Disorders Market Forecast and Analysis
7.7. OTHERS
7.7.1. Overview
7.7.2. Others Market Forecast and Analysis
8. OPHTHALMIC DRUGS - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
8.1. OVERVIEW
8.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
8.3. ANTI-GLAUCOMA DRUG
8.3.1. Overview
8.3.2. Anti-Glaucoma Drug Market Forecast and Analysis
8.4. DRY EYE DRUG
8.4.1. Overview
8.4.2. Dry Eye Drug Market Forecast and Analysis
8.5. OPHTHALMIC ANTI-ALLERGY/INFLAMMATORY
8.5.1. Overview
8.5.2. Ophthalmic Anti-Allergy/Inflammatory Market Forecast and Analysis
8.6. RETINAL DRUG
8.6.1. Overview
8.6.2. Retinal drug Market Forecast and Analysis
8.7. OTHERS
8.7.1. Overview
8.7.2. Others Market Forecast and Analysis
9. OPHTHALMIC DRUGS - REVENUE AND FORECASTS TO 2028 - PRODUCT TYPE
9.1. OVERVIEW
9.2. PRODUCT TYPE MARKET FORECASTS AND ANALYSIS
9.3. OTC DRUG
9.3.1. Overview
9.3.2. OTC Drug Market Forecast and Analysis
9.4. PRESCRIPTION DRUG
9.4.1. Overview
9.4.2. Prescription Drug Market Forecast and Analysis
10. OPHTHALMIC DRUGS REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Ophthalmic Drugs Overview
10.1.2 North America Ophthalmic Drugs Forecasts and Analysis
10.1.3 North America Ophthalmic Drugs Forecasts and Analysis - By Disease
10.1.4 North America Ophthalmic Drugs Forecasts and Analysis - By Drug Class
10.1.5 North America Ophthalmic Drugs Forecasts and Analysis - By Product Type
10.1.6 North America Ophthalmic Drugs Forecasts and Analysis - By Countries
10.1.6.1 United States Ophthalmic Drugs
10.1.6.1.1 United States Ophthalmic Drugs by Disease
10.1.6.1.2 United States Ophthalmic Drugs by Drug Class
10.1.6.1.3 United States Ophthalmic Drugs by Product Type
10.1.6.2 Canada Ophthalmic Drugs
10.1.6.2.1 Canada Ophthalmic Drugs by Disease
10.1.6.2.2 Canada Ophthalmic Drugs by Drug Class
10.1.6.2.3 Canada Ophthalmic Drugs by Product Type
10.1.6.3 Mexico Ophthalmic Drugs
10.1.6.3.1 Mexico Ophthalmic Drugs by Disease
10.1.6.3.2 Mexico Ophthalmic Drugs by Drug Class
10.1.6.3.3 Mexico Ophthalmic Drugs by Product Type
10.2. EUROPE
10.2.1 Europe Ophthalmic Drugs Overview
10.2.2 Europe Ophthalmic Drugs Forecasts and Analysis
10.2.3 Europe Ophthalmic Drugs Forecasts and Analysis - By Disease
10.2.4 Europe Ophthalmic Drugs Forecasts and Analysis - By Drug Class
10.2.5 Europe Ophthalmic Drugs Forecasts and Analysis - By Product Type
10.2.6 Europe Ophthalmic Drugs Forecasts and Analysis - By Countries
10.2.6.1 Germany Ophthalmic Drugs
10.2.6.1.1 Germany Ophthalmic Drugs by Disease
10.2.6.1.2 Germany Ophthalmic Drugs by Drug Class
10.2.6.1.3 Germany Ophthalmic Drugs by Product Type
10.2.6.2 France Ophthalmic Drugs
10.2.6.2.1 France Ophthalmic Drugs by Disease
10.2.6.2.2 France Ophthalmic Drugs by Drug Class
10.2.6.2.3 France Ophthalmic Drugs by Product Type
10.2.6.3 Italy Ophthalmic Drugs
10.2.6.3.1 Italy Ophthalmic Drugs by Disease
10.2.6.3.2 Italy Ophthalmic Drugs by Drug Class
10.2.6.3.3 Italy Ophthalmic Drugs by Product Type
10.2.6.4 Spain Ophthalmic Drugs
10.2.6.4.1 Spain Ophthalmic Drugs by Disease
10.2.6.4.2 Spain Ophthalmic Drugs by Drug Class
10.2.6.4.3 Spain Ophthalmic Drugs by Product Type
10.2.6.5 United Kingdom Ophthalmic Drugs
10.2.6.5.1 United Kingdom Ophthalmic Drugs by Disease
10.2.6.5.2 United Kingdom Ophthalmic Drugs by Drug Class
10.2.6.5.3 United Kingdom Ophthalmic Drugs by Product Type
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Ophthalmic Drugs Overview
10.3.2 Asia-Pacific Ophthalmic Drugs Forecasts and Analysis
10.3.3 Asia-Pacific Ophthalmic Drugs Forecasts and Analysis - By Disease
10.3.4 Asia-Pacific Ophthalmic Drugs Forecasts and Analysis - By Drug Class
10.3.5 Asia-Pacific Ophthalmic Drugs Forecasts and Analysis - By Product Type
10.3.6 Asia-Pacific Ophthalmic Drugs Forecasts and Analysis - By Countries
10.3.6.1 Australia Ophthalmic Drugs
10.3.6.1.1 Australia Ophthalmic Drugs by Disease
10.3.6.1.2 Australia Ophthalmic Drugs by Drug Class
10.3.6.1.3 Australia Ophthalmic Drugs by Product Type
10.3.6.2 China Ophthalmic Drugs
10.3.6.2.1 China Ophthalmic Drugs by Disease
10.3.6.2.2 China Ophthalmic Drugs by Drug Class
10.3.6.2.3 China Ophthalmic Drugs by Product Type
10.3.6.3 India Ophthalmic Drugs
10.3.6.3.1 India Ophthalmic Drugs by Disease
10.3.6.3.2 India Ophthalmic Drugs by Drug Class
10.3.6.3.3 India Ophthalmic Drugs by Product Type
10.3.6.4 Japan Ophthalmic Drugs
10.3.6.4.1 Japan Ophthalmic Drugs by Disease
10.3.6.4.2 Japan Ophthalmic Drugs by Drug Class
10.3.6.4.3 Japan Ophthalmic Drugs by Product Type
10.3.6.5 South Korea Ophthalmic Drugs
10.3.6.5.1 South Korea Ophthalmic Drugs by Disease
10.3.6.5.2 South Korea Ophthalmic Drugs by Drug Class
10.3.6.5.3 South Korea Ophthalmic Drugs by Product Type
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Ophthalmic Drugs Overview
10.4.2 Middle East and Africa Ophthalmic Drugs Forecasts and Analysis
10.4.3 Middle East and Africa Ophthalmic Drugs Forecasts and Analysis - By Disease
10.4.4 Middle East and Africa Ophthalmic Drugs Forecasts and Analysis - By Drug Class
10.4.5 Middle East and Africa Ophthalmic Drugs Forecasts and Analysis - By Product Type
10.4.6 Middle East and Africa Ophthalmic Drugs Forecasts and Analysis - By Countries
10.4.6.1 South Africa Ophthalmic Drugs
10.4.6.1.1 South Africa Ophthalmic Drugs by Disease
10.4.6.1.2 South Africa Ophthalmic Drugs by Drug Class
10.4.6.1.3 South Africa Ophthalmic Drugs by Product Type
10.4.6.2 Saudi Arabia Ophthalmic Drugs
10.4.6.2.1 Saudi Arabia Ophthalmic Drugs by Disease
10.4.6.2.2 Saudi Arabia Ophthalmic Drugs by Drug Class
10.4.6.2.3 Saudi Arabia Ophthalmic Drugs by Product Type
10.4.6.3 U.A.E Ophthalmic Drugs
10.4.6.3.1 U.A.E Ophthalmic Drugs by Disease
10.4.6.3.2 U.A.E Ophthalmic Drugs by Drug Class
10.4.6.3.3 U.A.E Ophthalmic Drugs by Product Type
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Ophthalmic Drugs Overview
10.5.2 South and Central America Ophthalmic Drugs Forecasts and Analysis
10.5.3 South and Central America Ophthalmic Drugs Forecasts and Analysis - By Disease
10.5.4 South and Central America Ophthalmic Drugs Forecasts and Analysis - By Drug Class
10.5.5 South and Central America Ophthalmic Drugs Forecasts and Analysis - By Product Type
10.5.6 South and Central America Ophthalmic Drugs Forecasts and Analysis - By Countries
10.5.6.1 Brazil Ophthalmic Drugs
10.5.6.1.1 Brazil Ophthalmic Drugs by Disease
10.5.6.1.2 Brazil Ophthalmic Drugs by Drug Class
10.5.6.1.3 Brazil Ophthalmic Drugs by Product Type
10.5.6.2 Argentina Ophthalmic Drugs
10.5.6.2.1 Argentina Ophthalmic Drugs by Disease
10.5.6.2.2 Argentina Ophthalmic Drugs by Drug Class
10.5.6.2.3 Argentina Ophthalmic Drugs by Product Type
10.5.6.3 Chile Ophthalmic Drugs
10.5.6.3.1 Chile Ophthalmic Drugs by Disease
10.5.6.3.2 Chile Ophthalmic Drugs by Drug Class
10.5.6.3.3 Chile Ophthalmic Drugs by Product Type
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. OPHTHALMIC DRUGS, KEY COMPANY PROFILES
12.1. AERIE PHARMACEUTICALS, INC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ALLERGAN
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. BAUSCH HEALTH COMPANIES INC.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. SANTEN PHARMACEUTICAL CO., LTD.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. REGENERON
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. NOVARTIS AG
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. BAYER AG
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. OTSUKA PHARMACEUTICAL CO., LTD.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. F. HOFFMANN-LA ROCHE LTD
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. PFIZER
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Aerie Pharmaceuticals, Inc.
2. Allergan
3. Bausch Health Companies Inc.
4. Santen Pharmaceutical Co., Ltd.
5. Regeneron
6. Novartis AG
7. Bayer AG
8. Otsuka Pharmaceutical Co., Ltd.
9. F. Hoffmann-La Roche Ltd
10. Pfizer
TIPRE00008651
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market




Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak To Analyst
Pricing
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount